Originally reported by hastingstribune. Read more
Archive summary Clinical & research
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business ...
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‐of‐Phase 2 meeting with the U.S. Food and Drug AdministrationOn-track for VLS-01 Phase 2 Elumina trial topline data readout anticipated in H2...
Newsletter
The weekly digest
Weekly digest of US behavioral health policy and regulation, source-linked and practitioner-edited. Free; unsubscribe in one click.